Full Text View
Tabular View
No Study Results Posted
Related Studies
Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer (READ)
This study has been completed.
Study NCT00689156   Information provided by Danish Breast Cancer Cooperative Group

First Received on May 29, 2008.   Last Updated on January 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
docetaxel, cyclophosphamide
Additional drug interventions recognized in this trial
Cyclophosphamide
Docetaxel
Epirubicin
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Danish Breast Cancer Cooperative Group
Fonden til fremme af klinisk eksperimentel cancerforskning vedrørende c. mammae
Sanofi
Dako


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services